erlotinib has been researched along with acarbose in 2 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (acarbose) | Trials (acarbose) | Recent Studies (post-2010) (acarbose) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 131 | 0 | 122 |
| 221 | 0 | 180 | 118 | 0 | 86 |
| Protein | Taxonomy | erlotinib (IC50) | acarbose (IC50) |
|---|---|---|---|
| Alpha-amylase | Acarus siro | 3.8 | |
| Maltase-glucoamylase, intestinal | Homo sapiens (human) | 2 | |
| Pancreatic alpha-amylase | Sus scrofa (pig) | 4.3108 | |
| Alpha-amylase 1A | Homo sapiens (human) | 0.996 | |
| Lysosomal alpha-glucosidase | Homo sapiens (human) | 5 | |
| Sucrase-isomaltase, intestinal | Homo sapiens (human) | 2 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 2 | |
| Oligo-1,6-glucosidase IMA1 | Saccharomyces cerevisiae S288C | 9.37 | |
| Probable maltase-glucoamylase 2 | Homo sapiens (human) | 2 | |
| Chain A, Cyclomaltodextrin glucanotransferase | Bacillus sp. 1011 | 5600 | |
| Sucrase-isomaltase, intestinal | Rattus norvegicus (Norway rat) | 1.97 | |
| Lysosomal alpha-glucosidase | Rattus norvegicus (Norway rat) | 1.3892 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
1 review(s) available for erlotinib and acarbose
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for erlotinib and acarbose
| Article | Year |
|---|---|
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |